RxDoctor Payments Data

Cornell Peters, MD

Family Medicine · Macon, GANPI 1861487225

Payments from drug & device makers

$7,313in general payments, 2019–2025

Across 378 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$828
  • Novo Nordisk$793
  • AstraZeneca$575
  • Indivior Inc.$534
  • Lilly USA, LLC$462
  • Abbott$434
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$6,99796%
  • Education$2564%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,313 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$36,350
Medicare patients
89
Services billed
543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide45$60,371
EliquisApixaban67$54,480
OzempicSemaglutide40$53,159
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl257$52,827
JanuviaSitagliptin Phosphate41$50,424
MounjaroTirzepatide43$47,265
LinzessLinaclotide37$37,888
JardianceEmpagliflozin28$27,348
JanumetSitagliptin Phos/Metformin Hcl19$25,848
EntrestoSacubitril/Valsartan16$10,762
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,329
Dexlansoprazole DrDexlansoprazole18$4,947
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen117$3,740
Omeprazole218$3,442
Gabapentin227$3,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$793$113,53085 claims
MerckJanuvia, Janumet$67$76,27260 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Mitigare$86$54,832268 claims
PfizerEliquis$363$54,48067 claims
Lilly USA, LLCMounjaro$462$47,26543 claims
AbbVieLinzess$828$37,88837 claims
Boehringer IngelheimJardiance$258$27,34828 claims
NovartisEntresto$38$10,76216 claims
GSKAnoro Ellipta$41$5,32911 claims
Scilex Pharmaceuticals Inc.Colchicine$81$1,19421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →